HRT.so
Weight Loss Hormones
4.7 Rating
Subcutaneous injection (once weekly)

Semaglutide (Wegovy/Ozempic)

A GLP-1 receptor agonist that has revolutionized medical weight loss, producing average weight loss of 15-17% of body weight.

Overview

Semaglutide is a once-weekly GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic) and FDA-approved for chronic weight management (Wegovy). Clinical trials demonstrated unprecedented weight loss results, with participants losing an average of 15-17% of their body weight over 68 weeks.

How It Works

Semaglutide mimics the GLP-1 hormone, activating receptors in the brain that regulate appetite and food intake. It slows gastric emptying, increases satiety, and reduces hunger signals. The net effect is significant reduction in caloric intake and sustained weight loss.

Benefits

Significant sustained weight loss
Improved cardiovascular markers
Reduced insulin resistance
Appetite suppression
Once-weekly dosing
Cardiovascular risk reduction

Potential Side Effects

Nausea
Vomiting
Diarrhea
Constipation
Abdominal pain
Gallbladder issues

Dosage Information

Wegovy: Started at 0.25mg weekly, escalated over 16 weeks to maintenance dose of 2.4mg weekly. Ozempic (off-label for weight loss): 0.25mg to 2mg weekly.

Quick Facts

Administration

Subcutaneous injection (once weekly)

Rating

4.7 / 5.0

Category

Weight Loss Hormones

Common Symptoms

Obesity (BMI ≥30)
Overweight with comorbidities (BMI ≥27)
Failed diet and exercise
Insulin resistance
Available Providers

JoinFridays

Starting at $117/month

9.68

Shed

10% off first month

9.64

TrimRx

Starting at $147/month

9.6
Compare All Providers
Related Treatments
Tirzepatide (Mounjaro/Zepbound)Liraglutide (Saxenda)

Common Questions

Find a Provider for Semaglutide (Wegovy/Ozempic)

Compare top providers offering this treatment.

Compare Providers